ClinicalTrials.gg
Not yet recruitingNCT07879495Updated Oct 16, 2026

Alveolar Ridge Preservation (ARP) Study Using Alloplastic Biomaterial and a Resorbable Synthetic Membrane. A Digital Workflow (CBCT/Scanner) Evaluates Hard and Soft Tissue Volumetric Changes at 4 Months, Validating Support for the Gingival Phenotype and Buccal Bone Plate.

A Phase 1/2 interventional study of Alveolar Ridge Preservation using a synthetic alloplastic bone substitute and a resorbable polymer membrane and Minimally invasive flapless tooth extraction followed by unassisted spontaneous healing in Alveolar Ridge Augmentation, Bone Substitutes and Guided Tissue Regeneration, Periodontal, sponsored by Universidad Católica San Antonio de Murcia. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Universidad Católica San Antonio de Murcia · Phase 1/2, Interventional, and Health services research

Updated Oct 16, 2026Newly registeredGo to Updates ↓
Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The dimensional collapse of the alveolar ridge following tooth extraction represents a critical challenge for implant rehabilitation. This research proposes an alveolar ridge preservation (ARP) protocol based on the combination of a slow-resorbing alloplastic synthetic biomaterial and a polymer-based resorbable synthetic membrane. Through a digital workflow integrating cone-beam computed tomography (CBCT) and intraoral scanning (Carestream 3800), volumetric changes in hard and soft tissues will be monitored. The study will compare baseline conditions with outcomes at 4 months of healing, analyzing whether the use of the membrane ensures adequate support for the gingival phenotype and minimizes buccal bone plate resorption.

02

Conditions studied

  • Alveolar Ridge Augmentation
  • Bone Substitutes
  • Guided Tissue Regeneration, Periodontal
  • Cone-Beam Computed Tomography
  • Bone Resorption

Browse trials for

03

In context

Bone Resorption

158 studies on the registry are indexed under Bone Resorption; 26 are open to participants now.

This study's planned enrollment of 28 is above the median of 24 across 137 interventional studies indexed under Bone Resorption.

Browse Bone Resorption studies →

Lead sponsor

Universidad Católica San Antonio de Murcia is the lead sponsor of 138 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>18 years of age) with full cognitive capacity to understand and sign the Informed Consent approved by the UCAM Ethics Committee (in accordance with the 2022-23 Regulation).
  • Presence of at least one non-restorable mandibular premolar (first or second) or first mandibular molar with a clear indication for extraction and subsequent implant-supported prosthetic rehabilitation.
  • Buccal Bone Plate Integrity: Clinically intact buccal bone wall following baseline clinical examination and tomographic confirmation (T0 CBCT), presenting a continuous residual thickness of at least 1 mm, with no evidence of bone dehiscences or fenestrations prior to surgery (Type 1 sockets according to the Elian / Juodzbalys classification).
  • Absence of Active Infectious Processes: Surgical site free of signs of acute or exacerbated chronic infection. This excludes the presence of active suppuration, productive fistulas, periodontal abscesses, or extensive osteolytic periapical lesions (>2 mm in radiographic diameter) that could alter tissue pH or destabilize the biomaterial.
  • Adequate or stabilized general periodontal health, defined by a Full-Mouth Plaque Score (FMPS) ≤ 20% and Full-Mouth Bleeding Score (FMBS) ≤ 20%.

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled systemic medical conditions that compromise bone or mucosal healing (e.g., Diabetes Mellitus with HbA1c >7%, severe calcium metabolism disorders, severe hepatopathies, or nephropathies).
  • Patients undergoing active treatment with drugs that alter bone remodeling, such as systemic bisphosphonates (oral or intravenous), denosumab, or prolonged systemic corticosteroid therapies.
  • History of previous radiotherapy in the head and neck region, or active medical oncology.
  • Heavy smokers (>10 cigarettes per day) due to the demonstrated deleterious impact of nicotine on angiogenesis and gingival collagen maturation, or substance abuse.
  • Pregnant or actively lactating women at the time of inclusion.
  • Any defect, intraoperative fracture, or unforeseen lesion detected in the buccal bone plate during the surgical extraction maneuver that compromises the baseline condition of alveolar wall integrity.
  • Patient inability to attend the rigorous follow-up appointments scheduled at 4 months, or severe claustrophobia preventing the acquisition of records via CBCT or intraoral scanning with the CS 3800.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Experimental: Alveolar Ridge Preservation (ARP) utilizing a Slow-Resorbing Synthetic Alloplast and a

    Following atraumatic tooth extraction and rigorous socket debridement, the alveolar defect will be grafted with a slow-resorbing synthetic alloplastic bone substitute. A resorbable polymer-based synthetic barrier membrane will be adapted over the graft material. The surgical site will be managed via a \[flapped / flapless\] approach and stabilizing sutures will be placed to allow for \[primary / secondary\] intention healing. No loading or prosthetic provisionalization will be applied over the grafted socket during the 4-month healing period.

    Procedure: Alveolar Ridge Preservation using a synthetic alloplastic bone substitute and a resorbable polymer membrane

  • Other
    No Intervention: Unassisted Spontaneous Healing (Natural Blood Clot)

    Following atraumatic tooth extraction and rigorous socket debridement, the alveolar defect will be left to heal spontaneously without the application of any bone graft material or barrier membrane. A natural blood clot will be allowed to form and stabilize within the socket. The surgical site will be managed strictly via a flapless approach, with stabilizing sutures placed only if necessary to secure the coagulum and achieve hemostasis. The socket will undergo unassisted secondary intention healing during the 4-month observation period prior to implant placement evaluation.

    Procedure: Minimally invasive flapless tooth extraction followed by unassisted spontaneous healing

Interventions

  • ProcedureAlveolar Ridge Preservation using a synthetic alloplastic bone substitute and a resorbable polymer membrane

    This experimental intervention is distinguished by a fully synthetic, animal-free grafting protocol. Following a strictly flapless tooth extraction to preserve periosteal blood supply to the buccal bundle bone, the socket is grafted with a slow-resorbing synthetic alloplastic bone substitute, designed to act as a long-term space maintainer rather than a rapidly turning-over material. Crucially, the graft is covered by a polymer-based resorbable synthetic membrane, distinguishing it from standard protocols utilizing native or cross-linked collagen. The membrane is stabilized using non-resorbable cross-mattress sutures. To prevent distortion of the mucogingival junction, no periosteal releasing incisions are performed, and the site is left to heal by secondary intention with the membrane intentionally left exposed to the oral environment

  • ProcedureMinimally invasive flapless tooth extraction followed by unassisted spontaneous healing

    This control intervention is strictly distinguished by the complete absence of any ridge preservation biomaterials. It represents the baseline dimensional collapse of the alveolar ridge. Following a minimally invasive, flapless tooth extraction identical to the experimental arm, the socket is vigorously debrided but left unassisted to heal via a natural blood clot. To distinguish this true negative control from active comparators, no hemostatic agents (e.g., oxidized regenerated cellulose or gelatin sponges) are placed within the alveolus. Sutures are applied strictly to stabilize the existing gingival margins and secure the coagulum, allowing physiological secondary intention healing without any artificial space maintenance

06

What researchers measure

Primary outcomes

  1. Absolute Volumetric Change of the Alveolar Ridge Contour

    The primary outcome is the total volumetric alteration of the alveolar ridge, encompassing combined hard and soft tissue dimensional changes. This will be quantified in cubic millimeters (mm\^3) through a digital superimposition protocol. Baseline (Day 0) intraoral surface scans (STL) and Cone-Beam Computed Tomography (CBCT) DICOM files will be spatially aligned with 4-month (T1) postoperative STL and CBCT datasets using specialized image analysis software. A standardized Region of Interest (ROI) will be established using stable anatomical landmarks (e.g., adjacent teeth, hard palate) to calculate the absolute volume loss or gain

    Time frame: Baseline (Day 0, immediately post-extraction) and at 4 months post-operative.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07879495
Responsible party
Carlos Pérez-Albacete Martínez (Dr. Carlos Pérez-Albacete Martínez, Universidad Católica San Antonio de Murcia) — Principal investigator
First posted
Oct 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion